| Protocol ID | NCT05143892 |
| Registration Date | 2021-12-03 |
| Status | Unknown Status |
| Sponsor | The First Affiliated Hospital of Soochow University |
| Country | China |
| Industry | not industry |
| Blinding | unblinded |
| Center Type | singel-center RCT |
| Scope | national RCT |
| First Patient In | 2021-12-01 |
| Last Patient Out | 2023-11-30 |
| Publication | n |
| Gender % | ALL |
| Mean Age | 18 Years - 60 Years |
NCT05143892
Study on Avatrombopag for the Promotion of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation
| Field |
GLM
glm-5.1 11158ms / 8898 tok |
CLAUDE
claude-sonnet-4-20250514 5657ms / 10169 tok |
OPENAI
gpt-4o 4049ms / 8710 tok |
Review |
|---|---|---|---|---|
| rct_type | parallel RCT | parallel RCT | parallel RCT | OK |
| cancer_status | Cancer | Cancer | Cancer | OK |
| non_cancer_spec | N/A | N/A | N/A | OK |
| setting_patient | inpatient | inpatient | inpatient | OK |
| setting_place | hospital | hospital | hospital | OK |
| feasibility | feasibility RCT | feasibility RCT | feasibility RCT | OK |
| intervention_pharmacologic | yes | yes | yes | OK |
| intervention_chemo_immuno_radio | no | no | no | OK |
| intervention_complementary | no | no | no | OK |
| intervention_device | no | no | no | OK |
| intervention_psychological | no | no | no | OK |
| intervention_complex | no | no | no | OK |
| intervention_acp | no | no | no | OK |
| intervention_music | no | no | no | OK |
| intervention_screening | no | no | no | OK |
| intervention_palliative | no | no | no | OK |
| intervention_education | no | no | no | OK |
| intervention_digital | no | no | no | OK |
| intervention_other | no | no | no | OK |
| outcome_symptom | no | no | no | OK |
| outcome_qol | no | no | no | OK |
| outcome_dignity | no | no | no | OK |
| outcome_cost | no | no | no | OK |
| outcome_other | yes | yes | yes | OK |
| pharmacologic_sub |
other
other → other
shaky reasoning✓ Unanimous
Initial: other
Requery: other — Avatrombopag is a thrombopoietin receptor agonist that does not fit into the specified sub-categories like chemotherapy, immunotherapy, or controlled substances.
|
other
other → other
shaky reasoning✓ Unanimous
Initial: other
Requery: other — Avatrombopag is a thrombopoietin receptor agonist used to promote platelet engraftment, which is a specialized pharmacologic intervention that doesn't fit into the other specific categories.
|
other
off label use → other
shaky reasoning✓ Unanimous
Initial: off label use
Requery: other — Avatrombopag is a thrombopoietin receptor agonist, a pharmacologic intervention used to stimulate platelet production, not fitting any of the specific categories listed.
|
OK |